Results from the PARTNER Trial (Cohort B), comparing inoperable patients with severe aortic stenosis treated with the Edwards‘ SAPIEN transcatheter heart valve vs standard non-surgical therapy, continue to show great promise at two years. This comes at a time when the valve was just recently approved by the FDA.
Edwards Lifesciences announced that mortality for patients treated with transcatheter aortic valve replacement (TAVR) remained superior to standard therapy, with the mortality curves diverging further to rates of 43.3 percent versus 67.6 percent, respectively (compared to 30.7 and 50.7). The TAVR group did demonstrate a higher neurologic event rate compared to standard therapy. Furthermore the median days alive out of the hospital was 699 days in TAVR group verse 355 days for the standard group. The device continues to show promise for those inoperable candidates with severe aortic stenosis.
Link: Edwards SAPIEN Valve’s Patient Benefits Increase at Two Years
Product page: SAPIEN Transcatheter Heart Valve
Flashbacks: Transcatheter Aortic-Valve Implantation (TAVI) Reduces Mortality Rate Compared to Standard Therapy; Edwards Touts Results of SAPIEN Valve Study; SAPIEN Transcatheter Cardiac Valve Trial Going Ahead; Edwards Sapien Transcatheter Aortic Valve Makes Human Debut; Edwards Trials Company’s Minimally-Invasive Pulmonic Valve